全文获取类型
收费全文 | 215857篇 |
免费 | 16063篇 |
国内免费 | 938篇 |
专业分类
耳鼻咽喉 | 2333篇 |
儿科学 | 5554篇 |
妇产科学 | 4430篇 |
基础医学 | 27804篇 |
口腔科学 | 4628篇 |
临床医学 | 20608篇 |
内科学 | 45888篇 |
皮肤病学 | 2846篇 |
神经病学 | 20754篇 |
特种医学 | 7132篇 |
外国民族医学 | 14篇 |
外科学 | 33587篇 |
综合类 | 4114篇 |
现状与发展 | 3篇 |
一般理论 | 293篇 |
预防医学 | 19400篇 |
眼科学 | 4561篇 |
药学 | 14892篇 |
5篇 | |
中国医学 | 624篇 |
肿瘤学 | 13388篇 |
出版年
2023年 | 909篇 |
2022年 | 1579篇 |
2021年 | 3702篇 |
2020年 | 2326篇 |
2019年 | 3642篇 |
2018年 | 4197篇 |
2017年 | 3463篇 |
2016年 | 3653篇 |
2015年 | 4401篇 |
2014年 | 6433篇 |
2013年 | 9162篇 |
2012年 | 13504篇 |
2011年 | 14702篇 |
2010年 | 8413篇 |
2009年 | 7559篇 |
2008年 | 13821篇 |
2007年 | 14644篇 |
2006年 | 14120篇 |
2005年 | 14621篇 |
2004年 | 13972篇 |
2003年 | 13053篇 |
2002年 | 12598篇 |
2001年 | 2004篇 |
2000年 | 1573篇 |
1999年 | 2169篇 |
1998年 | 2900篇 |
1997年 | 2501篇 |
1996年 | 2263篇 |
1995年 | 2011篇 |
1994年 | 1796篇 |
1993年 | 1691篇 |
1992年 | 1254篇 |
1991年 | 1194篇 |
1990年 | 1092篇 |
1989年 | 996篇 |
1988年 | 1052篇 |
1987年 | 1054篇 |
1986年 | 1034篇 |
1985年 | 1131篇 |
1984年 | 1506篇 |
1983年 | 1483篇 |
1982年 | 1825篇 |
1981年 | 1652篇 |
1980年 | 1559篇 |
1979年 | 826篇 |
1978年 | 969篇 |
1977年 | 938篇 |
1976年 | 835篇 |
1975年 | 687篇 |
1974年 | 679篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
目的分析成人血液系统恶性肿瘤患者接受强烈化疗后中性粒细胞减少性肠炎(NE)的发生率、危险因素及预后情况。方法收集2004至2013年接受化疗的1804例血液系统恶性肿瘤患者,记录患者血常规、凝血检测和血液生化检测结果,并记录患者年龄、性别、原发病、既往化疗次数、既往化疗方案中是否使用阿糖胞苷、临床症状、肠壁厚度、中性粒细胞最低计数、中性粒细胞缺乏持续时间、NE的治疗方法和预后等,探讨NE起病诱因、临床特征、腹部B超特点、症状的预后意义及化疗药物对发病的影响等。结果1804例患者中226例(12.5%)化疗后合并NE,化疗后10~19d起病,中位起病时间为化疗后第14天。发生NE后26例患者死亡,病死率11.5%。化疗药物包括阿糖胞苷、临床症状≥4项、中性粒细胞缺乏持续超过7d以及B超下肠壁厚度≥10mm的患者病死率相对较高。结论NE是接受强烈化疗的血液系统肿瘤患者的严重的并发症,发生NE后患者病死率较高。 相似文献
6.
7.
8.
Clint R. Bellenger John B. Arnold Jonathan D. Buckley Dominic Thewlis Joel T. Fuller 《Journal of Science and Medicine in Sport》2019,22(3):294-299
Objectives
To investigate whether functional overreaching affects locomotor system behaviour when running at fixed relative intensities and if any effects were associated with changes in running performance.Design
Prospective intervention study.Methods
Ten trained male runners completed three training blocks in a fixed order. Training consisted of one week of light training (baseline), two weeks of heavy training designed to induce functional overreaching, and ten days of light taper training designed to allow athletes to recover from, and adapt to, the heavy training. Locomotor behaviour, 5-km time trial performance, and subjective reports of training status (Daily Analysis of Life Demands for Athletes (DALDA) questionnaire) were assessed at the completion of each training block. Locomotor behaviour was assessed using detrended fluctuation analysis of stride intervals during running at speeds corresponding to 65% and 85% of maximum heart rate (HRmax) at baseline.Results
Time trial performance (effect size ±95% confidence interval (ES): 0.16 ± 0.06; p < 0.001), locomotor behaviour at 65% HRmax (ES: ?1.12 ± 0.95; p = 0.026), and DALDA (ES: 2.55 ± 0.80; p < 0.001) were all detrimentally affected by the heavy training. Time trial performance improved relative to baseline after the taper (ES: ?0.16 ± 0.10; p = 0.003) but locomotor behaviour at 65% HRmax (ES: ?1.18 ± 1.17; p = 0.048) and DALDA (ES: 0.92 ± 0.90; p = 0.045) remained impaired.Conclusions
Locomotor behaviour during running at 65% HRmax was impaired by functional overreaching and remained impaired after a 10-day taper, despite improved running performance. Locomotor changes may increase injury risk and should be considered within athlete monitoring programs independently of performance changes. 相似文献9.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献10.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288